Efluelda
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05048589 | Oct 2021 → May 2022 | influenza | Tor Biering-Sørensen | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07485855 | Dec 2025 → Apr 2027 expected | hematopoietic and lymphoid cell neoplasm, influenza | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT04137887 | Nov 2019 → May 2020 | — | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06506812 | May 2025 | influenza | Tor Biering-Sørensen | Completed | No outcome recorded |
| Phase 4 | NCT06141655 | Oct 2023 → May 2025 | influenza | Federico Martinón Torres | Completed | No outcome recorded |
| Phase 4 | NCT05517174 | Sep 2022 → May 2025 | influenza | Tor Biering-Sørensen | Completed | No outcome recorded |
| Phase 4 | NCT05154383 | Nov 2021 → Jul 2022 | — | Centre Hospitalier Annecy Genevois | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-22 | Sanofi | Media Update: Survey: Physicians and pharmacists would tell CDC to recommend vaccine like Fluzone High-Dose Quadrivalent (Influenza Vaccine) for people 65 years and older sanofi.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EFLUELDA | “This randomized controlled trial aims to compare the immunogenicity of three influenza vaccine formulations - high-dose trivalent inactivated vaccine (HD-IIV3; Efluelda),...” NCT07485855 ↗5“For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.” NCT05517174 ↗ “For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.” NCT06506812 ↗ “the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used” NCT05048589 ↗ “EFLUELDA, Suspension for injection, one dose” NCT06141655 ↗ |
| Known as | Fluzone High-Dose Quadrivalent | “For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.” NCT05517174 ↗2“For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.” NCT06506812 ↗ “the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used” NCT05048589 ↗ |
| Known as | HD-IIV3 | “This randomized controlled trial aims to compare the immunogenicity of three influenza vaccine formulations - high-dose trivalent inactivated vaccine (HD-IIV3; Efluelda),...” NCT07485855 ↗ |
| Known as | Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04137887 ↗ |
| Modality | Vaccine | “Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)” NCT04137887 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular” NCT04137887 ↗ |